Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Expression of Genes for Methylxanthine Pathway-Associated Enzymes Accompanied by Sex Steroid Receptor Status Impacts Breast Carcinoma Progression.

Wittliff JL, Sereff SB, Daniels MW.

Horm Cancer. 2017 Dec;8(5-6):298-313. doi: 10.1007/s12672-017-0309-2. Epub 2017 Oct 2.

PMID:
28971320
2.

Clinical outcomes linked to expression of gene subsets for protein hormones and their cognate receptors from LCM-procured breast carcinoma cells.

Daniels MW, Brock GN, Wittliff JL.

Breast Cancer Res Treat. 2017 Jan;161(2):245-258. doi: 10.1007/s10549-016-4049-8. Epub 2016 Nov 17.

PMID:
27858316
3.

Interaction between smoking history and gene expression levels impacts survival of breast cancer patients.

Andres SA, Bickett KE, Alatoum MA, Kalbfleisch TS, Brock GN, Wittliff JL.

Breast Cancer Res Treat. 2015 Aug;152(3):545-56. doi: 10.1007/s10549-015-3507-z. Epub 2015 Jul 23.

PMID:
26202054
4.

Temporal Expression of miRNAs in Laser Capture Microdissected Palate Medial Edge Epithelium from Tgfβ3(-/-) Mouse Fetuses.

Warner D, Ding J, Mukhopadhyay P, Brock G, Smolenkova IA, Seelan RS, Webb CL, Wittliff JL, Greene RM, Pisano MM.

Microrna. 2015;4(1):64-71.

PMID:
26159804
5.

A systems biology approach identifies a regulatory network in parotid acinar cell terminal differentiation.

Metzler MA, Venkatesh SG, Lakshmanan J, Carenbauer AL, Perez SM, Andres SA, Appana S, Brock GN, Wittliff JL, Darling DS.

PLoS One. 2015 Apr 30;10(4):e0125153. doi: 10.1371/journal.pone.0125153. eCollection 2015. Erratum in: PLoS One. 2015;10(6):e0131853.

6.

Gender-associated expression of tumor markers and a small gene set in breast carcinoma.

Andres SA, Smolenkova IA, Wittliff JL.

Breast. 2014 Jun;23(3):226-33. doi: 10.1016/j.breast.2014.02.007. Epub 2014 Mar 21.

PMID:
24656773
7.

Epigenetic analysis of laser capture microdissected fetal epithelia.

Seelan RS, Warner DR, Mukhopadhyay PM, Andres SA, Smolenkova IA, Wittliff JL, Michele Pisano M, Greene RM.

Anal Biochem. 2013 Nov 1;442(1):68-74. doi: 10.1016/j.ab.2013.07.029. Epub 2013 Jul 30.

8.

Characterization of estrogen response element binding proteins as biomarkers of breast cancer behavior.

Kruer TL, Cummins TD, Powell DW, Wittliff JL.

Clin Biochem. 2013 Nov;46(16-17):1739-46. doi: 10.1016/j.clinbiochem.2013.07.005. Epub 2013 Jul 16.

PMID:
23868020
9.

Interrogating differences in expression of targeted gene sets to predict breast cancer outcome.

Andres SA, Brock GN, Wittliff JL.

BMC Cancer. 2013 Jul 2;13:326. doi: 10.1186/1471-2407-13-326.

10.

Protein tyrosine phosphatase 4A2 expression predicts overall and disease-free survival of human breast cancer and is associated with estrogen and progestin receptor status.

Andres SA, Wittliff JL, Cheng A.

Horm Cancer. 2013 Aug;4(4):208-21. doi: 10.1007/s12672-013-0141-2. Epub 2013 Apr 9.

PMID:
23568563
11.

Assessment of phytoestrogen and mycoestrogen recognition by recombinant human estrogen receptor-α using ligand titration arrays.

Andres SA, Bumpus SB, Wittliff JL.

Phytochem Anal. 2013 Jul-Aug;24(4):357-66. doi: 10.1002/pca.2417. Epub 2013 Feb 8.

PMID:
23401334
12.

Co-expression of genes with estrogen receptor-α and progesterone receptor in human breast carcinoma tissue.

Andres SA, Wittliff JL.

Horm Mol Biol Clin Investig. 2012 Dec;12(1):377-90. doi: 10.1515/hmbci-2012-0025.

PMID:
25436697
13.
14.
15.

A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen.

Kerr DA 2nd, Wittliff JL.

Horm Cancer. 2011 Oct;2(5):261-71. doi: 10.1007/s12672-011-0080-8.

PMID:
21826535
16.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC; American Society of Clinical Oncology; College of American Pathologists.

Arch Pathol Lab Med. 2010 Jul;134(7):e48-72. doi: 10.1043/1543-2165-134.7.e48. Review.

PMID:
20586616
17.

Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival.

Kidd LR, Brock GN, VanCleave TT, Benford ML, Lavender NA, Kruer TL, Wittliff JL.

Cancer Causes Control. 2010 Oct;21(10):1545-57. doi: 10.1007/s10552-010-9583-9. Epub 2010 Jun 23.

18.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC.

Arch Pathol Lab Med. 2010 Jun;134(6):907-22. doi: 10.1043/1543-2165-134.6.907. Erratum in: Arch Pathol Lab Med. 2010 Aug;134(8):1101.

19.

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC.

J Clin Oncol. 2010 Jun 1;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529. Epub 2010 Apr 19. Review. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.

20.

Steroid receptor and growth factor receptor expression in human nonsmall cell lung cancers using cells procured by laser-capture microdissection.

Kerr A 2nd, Eliason JF, Wittliff JL.

Adv Exp Med Biol. 2008;617:377-84. doi: 10.1007/978-0-387-69080-3_36.

PMID:
18497061
21.

Molecular signatures of estrogen receptor-associated genes in breast cancer predict clinical outcome.

Wittliff JL, Kruer TL, Andres SA, Smolenkova I.

Adv Exp Med Biol. 2008;617:349-57. doi: 10.1007/978-0-387-69080-3_33.

PMID:
18497058
22.

Biosensors for detecting estrogen-like molecules and protein biomarkers.

Wittliff JL, Andres SA, Kruer TL, Kerr DA 2nd, Smolenkova IA, Erb JL.

Adv Exp Med Biol. 2008;614:315-22. doi: 10.1007/978-0-387-74911-2_35.

PMID:
18290342
23.

A three-tiered approach for calibration of a biosensor to detect estrogen mimics.

Andres SA, Kerr DA 2nd, Bumpus SB, Kruer TL, Thieman JW, Smolenkova IA, Wittliff JL.

Adv Exp Med Biol. 2008;614:305-13. doi: 10.1007/978-0-387-74911-2_34.

PMID:
18290341
24.

Potent inhibitors of LXXLL-based protein-protein interactions.

Galande AK, Bramlett KS, Trent JO, Burris TP, Wittliff JL, Spatola AF.

Chembiochem. 2005 Nov;6(11):1991-8.

PMID:
16222726
25.

Thioether side chain cyclization for helical peptide formation: inhibitors of estrogen receptor-coactivator interactions.

Galande AK, Bramlett KS, Burris TP, Wittliff JL, Spatola AF.

J Pept Res. 2004 Mar;63(3):297-302.

PMID:
15049842
26.

Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions.

Leduc AM, Trent JO, Wittliff JL, Bramlett KS, Briggs SL, Chirgadze NY, Wang Y, Burris TP, Spatola AF.

Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11273-8. Epub 2003 Sep 17.

27.

Laser capture microdissection and its applications in genomics and proteomics.

Wittliff JL, Erlander MG.

Methods Enzymol. 2002;356:12-25. No abstract available.

PMID:
12418184
28.

Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer.

Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL.

Int J Gynecol Cancer. 2000 Sep;10(5):372-381.

PMID:
11240701
29.

Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.

Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL, Wolmark N.

J Natl Cancer Inst. 2001 Jan 17;93(2):112-20.

PMID:
11208880
30.

Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.

Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL.

Gynecol Oncol. 2001 Jan;80(1):48-55.

PMID:
11136569
31.

Interaction of angiogenesis inhibitor TNP-470 with basic fibroblast growth factor receptors.

Bond SJ, Klein SA, Anderson GL, Wittliff JL.

J Surg Res. 2000 Jul;92(1):18-22.

PMID:
10864476
32.

Development of Kinetic Ligand-binding Assays Using a Fiber Optic Sensor.

Smith RH, Lemon WJ, Erb JL, Erb-Downward JR, Downward JG, Ulrich OE, Wittliff JL.

Clin Chem. 1999 Sep;45(9):1683-1685. No abstract available.

33.

Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer.

Srkalovic G, Schally AV, Wittliff JL, Day TG Jr, Jenison EL.

Int J Oncol. 1998 Mar;12(3):489-98.

PMID:
9472084
34.

Structural and functional analysis of N-terminal point mutants of the human estrogen receptor.

Graumann K, Wittliff JL, Raffelsberger W, Miles L, Jungbauer A, Butt TR.

J Steroid Biochem Mol Biol. 1996 Mar;57(5-6):293-300.

PMID:
8639465
35.

Quantitative analyses of epidermal growth factor receptors, HER-2/neu oncoprotein and cathepsin D in nonmalignant and malignant uteri.

Sanfilippo JS, Miseljic S, Yang AR, Doering DL, Shaheen RM, Wittliff JL.

Cancer. 1996 Feb 15;77(4):710-6.

PMID:
8616763
36.

Relation between cathepsin D expression and other prognostic factors in breast carcinomas.

Shaheen RM, Miseljic S, Wiehle RD, Wittliff JL.

Clin Chem. 1995 Nov;41(11):1585-91.

38.

Expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in colon disease.

Miseljic S, Galandiuk S, Myers SD, Wittliff JL.

J Clin Lab Anal. 1995;9(6):413-7.

PMID:
8587011
39.

Comparison of cathepsin D determinations in human carcinomas by enzyme immunoassay and immunoradiometric assay.

Shaheen RM, Miseljic S, Doering DL, Wittliff JL.

J Clin Lab Anal. 1995;9(6):351-8.

PMID:
8587002
40.

Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486.

Pinski J, Halmos G, Shirahige Y, Wittliff JL, Schally AV.

J Clin Endocrinol Metab. 1993 Nov;77(5):1388-92.

PMID:
8077338
41.

Bromodeoxyuridine labeling for S-phase measurement in breast carcinoma.

Meyer JS, Koehm SL, Hughes JM, Higa E, Wittliff JL, Lagos JA, Manes JL.

Cancer. 1993 Jun 1;71(11):3531-40.

PMID:
8490901
42.

Expression of hormone receptors, cathepsin D, and HER-2/neu oncoprotein in normal colon and colonic disease.

Galandiuk S, Miseljic S, Yang AR, Early M, McCoy MD, Wittliff JL.

Arch Surg. 1993 Jun;128(6):637-42.

PMID:
8099272
43.
44.
45.

Expression and characterization of an active human estrogen receptor as a ubiquitin fusion protein from Escherichia coli.

Wittliff JL, Wenz LL, Dong J, Nawaz Z, Butt TR.

J Biol Chem. 1990 Dec 15;265(35):22016-22.

PMID:
2174894
46.

Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.

Srkalovic G, Wittliff JL, Schally AV.

Cancer Res. 1990 Mar 15;50(6):1841-6. Erratum in: Cancer Res 1990 Jun 15;50(12):3808.

47.
48.

Influence of sialic acid on the binding activity of estrogen receptors.

van Aswegen CH, van Rensburg HG, Becker PJ, Wittliff JL, du Plessis DJ.

Clin Physiol Biochem. 1990;8(4):169-78.

PMID:
2078918
49.
50.

Detection of two high molecular weight hydrophobic forms of the human estrogen receptor.

Hyder SM, Wittliff JL.

J Steroid Biochem. 1989 Nov;33(5):965-70.

PMID:
2601342

Supplemental Content

Loading ...
Support Center